Primary source: European Medicines Agency (EMA)
PRAC recommended safety measures for Ixchiq, including updated product information and guidance for elderly use, based on the risk of aseptic meningitis and serious side effects.
This affects the benefit-risk profile of Ixchiq, particularly in elderly patients, and may require updates to labeling and risk minimization activities.
Update product information and guidance for use in elderly populations for Ixchiq; ensure compliance with PRAC recommendations.
Regulatory Intelligence Lead
Single event
Updated product information and guidance for use in elderly populations.
Update product information and guidance for use in elderly populations for Ixchiq; ensure compliance with PRAC recommendations.
EMA's PRAC concluded a review of Ixchiq (chikungunya vaccine) and recommended implementation of safety measures, including updates to product information and guidance for use in elderly populations, due to risks of aseptic meningitis and serious side effects.
What changed: PRAC recommended safety measures for Ixchiq, including updated product information and guidance for elderly use, based on the risk of aseptic meningitis and serious side effects.
Why it matters: This affects the benefit-risk profile of Ixchiq, particularly in elderly patients, and may require updates to labeling and risk minimization activities.
Practical implication: Update product information and guidance for use in elderly populations for Ixchiq; ensure compliance with PRAC recommendations.
Published from the Firecrawl agent regulatory extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
